<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365007">
  <stage>Registered</stage>
  <submitdate>24/09/2013</submitdate>
  <approvaldate>25/09/2013</approvaldate>
  <actrnumber>ACTRN12613001073796</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy Volunteers</studytitle>
    <scientifictitle>IPX233-B13-01:Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Attention Deficit Hyperactivity Disorder (ADHD)</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>An open-label, randomized, 4-sequence, 4-treatment, single-dose crossover study with at least 7 days of washout between each treatment period.
Treatment A:  1 capsule of IPX233-C0001 2 mg
Treatment B:  1 capsule of IPX233-C0002 2 mg
Treatment C:  1 tablet of IPX233-T0001 2 mg
Treatment D:  1 tablet of IPX233-T0002 2 mg


Postdose:
Measure BP (blood pressure), HR(heart rate) and RR(respiratory rate) at approximately 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours after dosing in each treatment period (subject should be supine for at least 5 minutes prior to measurements)
Conduct 12-lead ECG at approximately 2, 6 and 24 hours postdosing in each treatment period
</interventions>
    <comparator>Treatment D:  1 tablet of IPX233-T0002 2 mg
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics </outcome>
      <timepoint>A total of 15 blood samples (6 mL each) will be collected at the following timepoints after administration of IPX233 in each treatment period to quantify IPX233 and potential metabolites in plasma: Predose (up to 60 minutes prior to dosing), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours postdose.
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>12-lead electrocardiogram (ECGs), clinical laboratory tests, vital signs, adverse events (AEs), and concomitant medications will be evaluated over the course of the study.  Physical examinations will be performed at Screening and at Study Exit.  ECGs will be evaluated prior to the administration of IPX233 and after dosing in each treatment period.  
Postdose:
Measure BP (blood pressure), HR(heart rate) and RR(respiratory rate) at approximately 1, 2, 4, 6, 12, 24, 48, 72, and 96 hours after dosing in each treatment period (subject should be supine for at least 5 minutes prior to measurements)
Conduct 12-lead ECG at approximately 2, 6 and 24 hours postdosing in each treatment period

The possible adverse events (e.g. dry mouth, insomnia, constipation, etc.)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers between the ages of 18 and 55 years of age (inclusive) at the time of informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any history of drug or alcohol addiction or abuse within the last 5 years.
Presence of a clinically significant disorder including acute or chronic infections, or a malignant neoplasm, and/or involving disease in one or more of these organ systems:  cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, dermatologic, hepatic, reproductive, endocrine, or neurologic/psychiatric, as determined by clinical investigators.
History of or clinical signs of glaucoma, benign prostatic hypertrophy or urinary retention.
History of or clinical signs of any form of epilepsy or seizures.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>6/12/2013</anticipatedstartdate>
    <actualstartdate>6/12/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>14/01/2014</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Impax Pharmaceuticals,A Division of Impax Laboratories, Inc. </primarysponsorname>
    <primarysponsoraddress>31047 Genstar Road 
Hayward, CA 94544 
</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Impax Laboratories, Inc
</fundingname>
      <fundingaddress>30831 Huntwood Avenue
Hayward, CA 94544</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To characterize the pharmacokinetics (PK) of three IPX233 formulations (C0001, C0002, T0001) compared with one IPX233 formulation (T0002).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>71 Anzac Highway
Ashford, SA 5035
</ethicaddress>
      <ethicapprovaldate>19/11/2013</ethicapprovaldate>
      <hrec>2013-10-537</hrec>
      <ethicsubmitdate>7/10/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sepehr Shakib</name>
      <address>CMAX, a division of IDT Australia  Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000
</address>
      <phone>+61 08 8222-4638</phone>
      <fax />
      <email> sepehr.shakib@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Cmax</name>
      <address>Level 5 East Wing Royal Adelaide Hospital
North Terrace
Adelaide  SA  5000 
</address>
      <phone>1800 150 433</phone>
      <fax />
      <email> cmax@cmax.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sepehr Shakib</name>
      <address>CMAX, a division of IDT Australia  Limited
Level 5 East Wing
Royal Adelaide Hospital
North Terrace
Adelaide, SA 5000
</address>
      <phone>+61 08 8222-4638</phone>
      <fax />
      <email> sepehr.shakib@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>